European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques
- EU notifies
World Trade Organization (WTO) Members of its proposal for regulation of plants obtained from New Genomic Techniques (NGTs). - The notification asks for comments from
WTO members by30 December 2023 and is accompanied with a timetable for Parliamentary Votes. - Proposed regulation identifies a ‘conventional-like’ category of NGT products that would be regulated as conventional varieties, bringing EU policy closer to that of trading partners in
North and South America ,Australia ,India andJapan .
The proposal is a result of a
The proposal, which is part of a package of EU proposals to ensure resilient and sustainable use of the EU's natural resources, describes a category of NGTs producing modifications that could be obtained in nature or by conventional breeding. These are determined to be ‘conventional-like’ and, once verified, would be regulated in the same way as conventional varieties.
The proposal was adopted by the
Recent disclosures forecast that Members of the
“The ambitious schedule for adoption set out in the notification highlights significant progress within EU institutions that will be welcomed by trading partners, many of whom have introduced similar regulatory policy over the past eight years,” said
About Cibus
Cibus is a leader in gene edited productivity traits that address critical productivity and sustainability challenges for farmers such as diseases and pests which the
About the Cibus RTDS®-based High Throughput Breeding System
A key element of Cibus’ technology breakthrough is its high throughput breeding process (referred to as the Trait Machine™ System). The Trait Machine process is a crop specific application of Cibus’ patented Rapid Trait Development System™ (RTDS). The proprietary technologies in RTDS integrate crop specific cell biology platforms with a series of gene editing technologies to enable a system of end-to-end crop specific precision breeding. It is the core technology platform for Cibus’ Trait Machine: the first standardized end-to-end semi-automated crop specific gene editing system that directly edits a seed company’s elite germplasm. Each Trait Machine process requires a crop specific cell biology platform that enables Cibus to edit a single cell from a customers’ elite germplasm and grow that edited cell into a plant with the Cibus edits. Cibus has Trait Machine platforms developed for canola and rice and has already begun transferring back to customers their elite germplasm with Cibus edits.
The traits from Cibus’ RTDS-based high throughput breeding system are indistinguishable from traits developed using conventional breeding or from nature. Under the European Commission’s current proposal, if adopted, we expect that products from Cibus’ RTDS gene editing platform such as its pod shatter trait and Sclerotinia resistance traits for canola and winter oilseed rape will be considered ‘conventional-like'.
Cibus believes that RTDS and the Trait Machine process represent the technological breakthrough in plant breeding that is the ultimate promise of plant gene editing: high throughput gene editing systems operating as an extension of seed company breeding programs.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding the benefits of the Act, Cibus’ operational performance, and Cibus’ strategy, future operations, prospects and plans, are forward-looking statements. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could,” “would” and “will,” or the negative of these and similar expressions.
These forward-looking statements are based on the current expectations and assumptions of Cibus’ management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. There are many factors that could cause Cibus’ actual results, level of activity, performance or achievements to differ materially from those expressed or implied by forward-looking statements, including factors related to: (i) risks associated with the possible failure to realize certain anticipated benefits of the transactions contemplated by the merger (the “Transactions”), including with respect to future financial and operating results; (ii) the effect of the completion of the Transactions on Cibus’ business relationships, operating results and business generally; (iii) the outcome of any litigation related to the merger agreement or Transactions; (iv) competitive responses to the Transactions and changes in expected or existing competition; (v) challenges to Cibus’ intellectual property protection and unexpected costs associated with defending Cibus’ intellectual property rights; (vi) increased or unanticipated time and resources required for Cibus’ platform or trait product development efforts; (vii) Cibus’ reliance on third parties in connection with its development activities; (viii) Cibus’ ability to effectively license its productivity traits and sustainable ingredient products; (ix) the recognition of value in Cibus’ products by farmers, and the ability of farmers and processors to work effectively with crops containing Cibus’ traits; (x) Cibus’ ability to produce high-quality plants and seeds cost effectively on a large scale; (xi) Cibus’ need for additional funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; (xii) Cibus’ dependence on distributions from
Cibus Contacts:
Investor Relations
ktroeber@cibus.com
858-450-2636
Media Relations
colin@bioscribe.com
203-918-4347
Source: Cibus US LLC